152 related articles for article (PubMed ID: 35921177)
21. EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.
Sen N; Cross AM; Lorenzi PL; Khan J; Gryder BE; Kim S; Caplen NJ
Mol Carcinog; 2018 Oct; 57(10):1342-1357. PubMed ID: 29873416
[TBL] [Abstract][Full Text] [Related]
22. RUNX3 facilitates growth of Ewing sarcoma cells.
Bledsoe KL; McGee-Lawrence ME; Camilleri ET; Wang X; Riester SM; van Wijnen AJ; Oliveira AM; Westendorf JJ
J Cell Physiol; 2014 Dec; 229(12):2049-56. PubMed ID: 24812032
[TBL] [Abstract][Full Text] [Related]
23. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
[TBL] [Abstract][Full Text] [Related]
24. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
[TBL] [Abstract][Full Text] [Related]
25. Molecular pathogenesis of Ewing sarcoma: new therapeutic and transcriptional targets.
Lessnick SL; Ladanyi M
Annu Rev Pathol; 2012; 7():145-59. PubMed ID: 21942527
[TBL] [Abstract][Full Text] [Related]
26. A polypeptide from the junction region sequence of EWS-FLI1 inhibits Ewing's sarcoma cells, interacts with the EWS-FLI1 and partner proteins.
Thangaretnam KP; Gopisetty G; Ramanathan P; Rajkumar T
Sci Rep; 2017 Aug; 7(1):7172. PubMed ID: 28775288
[TBL] [Abstract][Full Text] [Related]
27. FOXM1 is an oncogenic mediator in Ewing Sarcoma.
Christensen L; Joo J; Lee S; Wai D; Triche TJ; May WA
PLoS One; 2013; 8(1):e54556. PubMed ID: 23365673
[TBL] [Abstract][Full Text] [Related]
28. Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma.
Sankar S; Bell R; Stephens B; Zhuo R; Sharma S; Bearss DJ; Lessnick SL
Oncogene; 2013 Oct; 32(42):5089-100. PubMed ID: 23178492
[TBL] [Abstract][Full Text] [Related]
29. EWS-FLI-1 regulates the neuronal repressor gene REST, which controls Ewing sarcoma growth and vascular morphology.
Zhou Z; Yu L; Kleinerman ES
Cancer; 2014 Feb; 120(4):579-88. PubMed ID: 24415532
[TBL] [Abstract][Full Text] [Related]
30. Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
Deng Q; Natesan R; Cidre-Aranaz F; Arif S; Liu Y; Rasool RU; Wang P; Mitchell-Velasquez E; Das CK; Vinca E; Cramer Z; Grohar PJ; Chou M; Kumar-Sinha C; Weber K; Eisinger-Mathason TSK; Grillet N; Grünewald TGP; Asangani IA
Cell Rep; 2022 Jun; 39(11):110971. PubMed ID: 35705030
[TBL] [Abstract][Full Text] [Related]
31. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
[TBL] [Abstract][Full Text] [Related]
32. C/EBPβ-1 promotes transformation and chemoresistance in Ewing sarcoma cells.
Gardiner JD; Abegglen LM; Huang X; Carter BE; Schackmann EA; Stucki M; Paxton CN; Lor Randall R; Amatruda JF; Putnam AR; Kovar H; Lessnick SL; Schiffman JD
Oncotarget; 2017 Apr; 8(16):26013-26026. PubMed ID: 28148901
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
34. Hippo pathway effectors YAP1/TAZ induce an EWS-FLI1-opposing gene signature and associate with disease progression in Ewing sarcoma.
Rodríguez-Núñez P; Romero-Pérez L; Amaral AT; Puerto-Camacho P; Jordán C; Marcilla D; Grünewald TG; Alonso J; de Alava E; Díaz-Martín J
J Pathol; 2020 Apr; 250(4):374-386. PubMed ID: 31880317
[TBL] [Abstract][Full Text] [Related]
35. Dual targeting of EWS-FLI1 activity and the associated DNA damage response with trabectedin and SN38 synergistically inhibits Ewing sarcoma cell growth.
Grohar PJ; Segars LE; Yeung C; Pommier Y; D'Incalci M; Mendoza A; Helman LJ
Clin Cancer Res; 2014 Mar; 20(5):1190-203. PubMed ID: 24277455
[TBL] [Abstract][Full Text] [Related]
36. EWS/FLI1 regulates EYA3 in Ewing sarcoma via modulation of miRNA-708, resulting in increased cell survival and chemoresistance.
Robin TP; Smith A; McKinsey E; Reaves L; Jedlicka P; Ford HL
Mol Cancer Res; 2012 Aug; 10(8):1098-108. PubMed ID: 22723308
[TBL] [Abstract][Full Text] [Related]
37. The Promoter-Associated Noncoding RNA
Palombo R; Frisone P; Fidaleo M; Mercatelli N; Sette C; Paronetto MP
Cancer Res; 2019 Jul; 79(14):3570-3582. PubMed ID: 31072811
[TBL] [Abstract][Full Text] [Related]
38. EWS-FLI1-regulated Serine Synthesis and Exogenous Serine are Necessary for Ewing Sarcoma Cellular Proliferation and Tumor Growth.
Issaq SH; Mendoza A; Kidner R; Rosales TI; Duveau DY; Heske CM; Rohde JM; Boxer MB; Thomas CJ; DeBerardinis RJ; Helman LJ
Mol Cancer Ther; 2020 Jul; 19(7):1520-1529. PubMed ID: 32371575
[TBL] [Abstract][Full Text] [Related]
39. Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma.
Goss KL; Gordon DJ
Oncotarget; 2016 Sep; 7(39):63003-63019. PubMed ID: 27557498
[TBL] [Abstract][Full Text] [Related]
40. Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor.
Osgood CL; Maloney N; Kidd CG; Kitchen-Goosen S; Segars L; Gebregiorgis M; Woldemichael GM; He M; Sankar S; Lessnick SL; Kang M; Smith M; Turner L; Madaj ZB; Winn ME; Núñez LE; González-Sabín J; Helman LJ; Morís F; Grohar PJ
Clin Cancer Res; 2016 Aug; 22(16):4105-18. PubMed ID: 26979396
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
